| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Repligen Corporation$141.01
-2.59 (-1.8%)
D 37Pipeline Score Tools & Services · Commercial
Market Cap
6.49 B
EPS
0.91
P/E Ratio
126.66 $
Value Trade
80.44 M
SEC Financials
Q1 2026Dilution Risk
Revenue
194.25 M
R&D Expenses
14.46 M
Operating CF
28.30 M
Total Assets
2.93 B
Total Liabilities
825.31 M
Equity
2.11 B
D/E Ratio
12,345
10.15 %
Week
-14.19 %
1 Month
-14.93 %
3 Month
-26.48 %
6 Month
-36.81 %
5 Year
922.76 %
All Time
Cash Data
Cash Position
784.53 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
875.27 K
52 Week Range
100.99 - 175.77
% held by Insiders
5.44 %
% held by Institutions
117.72 %
Enterprise Value
6.39 B
Total Shares
56.38 M
Short %
10.39 %
Float Shares
55.93 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Repligen Corporation
476Total events
0Upcoming
121Tier-1 (high impact)
2010 – 2026Coverage
Event history 2
TBD
▲Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | RG1068 (synthetic human secretin) | PDUFA Date | PDUFA | CRL | – | – | – |
— | RG1068 (synthetic human secretin) | PDUFA Date | PDUFA | CRL | – | – | – |
— | RG1068 (synthetic human secretin) | PDUFA Date | PDUFA | CRL | – | – | – |
Drug Pipeline Intelligence
D37
Pipeline Score $195M
Pipeline ValueValuation Signal
4
Drugs Scored0.1x
rNPV / MCap Top 54%
Small Cap (rank 421 of 913)
Percentile RankRepligen Corporation faces pipeline headwinds (37/100), with $600M risk-adjusted pipeline value, led by RG1068 in Autism (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RG1068 Small molecule | Pancreatitis | Phase 3 | NCT00660335 | 49% | $316M | COMPLETED | 258 | - | - | Oct 1, 2009 | - | Dec 3, 2009 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RG3039 | spinal muscular atrophy (SMA) | Phase 1 | 2012-04-25 | 90% inhibition of the target enzyme; well tolerated at all doses administered; no serious adverse events reported Read More | Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA) Read More | |
RG3039 | spinal muscular atrophy (SMA) | Phase 1 | 2012-04-25 | 90% inhibition of the target enzyme; well tolerated at all doses administered; no serious adverse events reported Read More | Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA) Read More | |
RG3039 | spinal muscular atrophy (SMA) | Phase 1 | 2012-04-25 | 90% inhibition of the target enzyme; well tolerated at all doses administered; no serious adverse events reported Read More | Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RGEN▲ +10.9%on this news
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation reported a strong second quarter for 2026, with revenues of $204 million, reflecting a 12% increase year-over-year. The company raised its full-year guidance for organic revenue growth and adjusted EPS, driven by robust market performance and the announcement of its acquisition of BioLife Solutions. Despite a decrease in GAAP EPS, the overall financial outlook remains positive.
Read more →RGENRepligen to Report Second Quarter 2026 Financial Results
Repligen Corporation announced it will report its second quarter 2026 financial results on July 28, 2026. A press release will precede the market opening, followed by a conference call at 8:00 a.m. ET to discuss the results. The call will be accessible for both domestic and international callers, and a webcast will be available on the company's website.
Read more →RGENRepligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation will present at the William Blair 46th Annual Growth Stock Conference on June 3rd. CEO Olivier Loeillot will provide a company overview during the event. A live webcast will be available for those unable to attend in person. Repligen focuses on bioprocessing technologies for biopharmaceutical manufacturing.
Read more →RGENRepligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Repligen Corporation has published its 2025 Corporate Sustainability Report, highlighting its commitment to sustainability across six key impact areas. The report includes disclosures aligned with the UN Sustainable Development Goals and various reporting frameworks. Key achievements include maintaining renewable energy in operations and adopting new sustainability policies. The company emphasizes transparency and continuous improvement in its sustainability efforts.
Read more →RGENRepligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
Repligen Corporation will present at the Bank of America Securities 2026 Global Healthcare Conference from May 12-14 in Las Vegas. CFO Jason Garland will lead an analyst discussion on May 12 at 10:00am PT. A live webcast of the presentation will be available on Repligen's Investor Relations website.
Read more →RGEN▲ +6.3%on this newsshared move
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • First quarter revenue
Repligen Corporation reported strong financial results for the first quarter of 2026, with a revenue of $194 million, representing a 15% increase from the previous year. The company also saw a 50% rise in GAAP EPS year-over-year and increased its adjusted EPS guidance for the full year to between $1.97 and $2.05. Key strategic initiatives include the launch of a Transformation Office, focusing on profitable growth and the recent divestiture of a non-core business. Furthermore, a new partnership in China aims to boost local manufacturing capabilities.
Read more →RGEN▲ +6.3%on this newsshared move
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation reported a strong first quarter for 2026, with revenues reaching $194 million, marking a 15% increase year-over-year. The company also saw significant growth in earnings per share, with a 50% rise in GAAP EPS. Repligen reiterated its guidance for organic revenue growth and adjusted EPS for the full year, reflecting confidence in its strategic initiatives and market position.
Read more →RGEN▼ -6.3%on this news
Repligen to Report First Quarter 2026 Financial Results
Repligen Corporation has announced that it will report its first quarter 2026 financial results on May 5, 2026. Ahead of the market opening, the company will issue a press release and host a conference call to discuss the financial performance for the period ending March 31, 2026. The conference call will be accessible to both domestic and international callers. Investors are reminded that there may be forward-looking statements subject to risks and uncertainties.
Read more →RGENRepligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
Repligen Corporation has inaugurated its new Training & Innovation Center in Breda, Netherlands, aimed at enhancing customer support through hands-on training and product demonstrations. This facility is the third of its kind globally, joining locations in Waltham and Tokyo. The opening reflects Repligen's commitment to investing in customer proximity and expanding its bioprocessing technology offerings.
Read more →RGENRepligen Corporation to Present at Upcoming March Conferences
Repligen Corporation will participate in three investor conferences in March 2026, including the Leerink Global Healthcare Conference and the Barclays Annual Global Healthcare Conference. CFO Jason Garland will lead discussions at both events, while CEO Olivier Loeillot will speak at the KeyBanc Virtual Healthcare Forum. Webcasts of the presentations will be available for investors.
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Repligen Corporation reported strong financial results for Q4 2025, achieving 14% organic growth, primarily driven by its Analytics and Proteins segments. The company exceeded its revenue guidance for the year and anticipates continued growth in 2026, despite facing a potential headwind from gene therapy. Repligen's CEO expressed optimism about their product portfolio and operational strategy moving forward.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance • Fourth quarter r
Repligen Corporation reported its fourth quarter and full year 2025 financial results, revealing impressive revenue growth of 18% year-over-year in Q4 and a total revenue of $738 million for the year. The company provided a positive revenue guidance for 2026, expecting to reach between $810 million to $840 million. This projection includes anticipated organic growth, alongside an improvement in adjusted operating margins. Notably, the company highlighted investments in its product portfolio and expansion in the Asia-Pacific region.
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen Corporation will announce its fourth quarter and full year 2025 financial results on February 24, 2026. A press release will precede the market opening, followed by a conference call at 8:30 a.m. ET to discuss the results. The call will be accessible to both domestic and international callers, with a webcast available on the company's website.
Read more →RGENRepligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
Repligen Corporation announced that Dr. Martin D. Madaus will succeed Tony Hunt as Chair of the Board, effective March 13, 2026. Tony Hunt, who has served for over a decade, will become an advisor until March 2027. The leadership transition is viewed positively, with both outgoing and incoming chairs expressing confidence in the company's future. Dr. Madaus brings extensive experience and is seen as well-qualified to lead Repligen moving forward.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN Executive chair tony hunt to retire; Dr. martin D. MadAus elected chair WALTHAM, MA
Repligen Corporation has announced the retirement of Executive Chair Tony Hunt, effective March 13, 2026, with Dr. Martin D. Madaus being elected as the new Chair of the Board. Repligen's President and CEO, Olivier Loeillot, praised Hunt's ten-year tenure for expanding the company's innovative product portfolio. Madaus, who has extensive experience in the life sciences and previously led Millipore Corporation, expressed honor in his new role and commitment to guiding the company forward. Hunt will remain as an advisor until March 2027 to ensure a seamless transition.
Read more →RGENRepligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Repligen Corporation has announced its participation in the upcoming J.P. Morgan 2026 Healthcare Conference scheduled for January 12 to 15 in San Francisco. The company's President and CEO, Olivier Loeillot, will present an overview of the company on January 13. A live webcast of the conference will be available on Repligen’s Investor Relations website, providing access for investors who cannot attend in person.
Read more →RGENRepligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
Repligen Corporation (NASDAQ:RGEN) has launched three new high-performance chromatography resins, including AVIPure® HiPer™ AAV9, AVIPure® HiPer™ AAV8, and HiPer™ QA anion exchange resin, to enhance its proteins portfolio. These innovations are aimed at supporting gene therapy developers by improving processing speed and molecule stability. Built on advanced Tantti™ DuloCore™ technology, these resins are expected to facilitate faster and more economical product development. Repligen is committed to providing cutting-edge tools as it anticipates further chromatography resin innovations in 2026.
Read more →RGENRepligen Corporation to Present at Evercore Healthcare Conference
Repligen Corporation will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Coral Gables, Florida. CFO Jason Garland is scheduled for an analyst-led discussion on December 3 at 1:20 p.m. ET. A live webcast will be available on the company's Investor Relations website, with a replay option following the event.
Read more →RGENRepligen Corporation to Present at Upcoming November Conferences
Repligen Corporation announced its participation in five upcoming investor conferences. The company focuses on bioprocessing technology and will provide live webcasts of the presentations. This initiative reflects Repligen's commitment to engaging with investors and showcasing its innovative solutions in the biopharmaceutical sector.
Read more →RGEN▼ -5.9%on this news
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Repligen Corporation reported strong financial results for Q3 2025, showcasing an 18% organic growth. The company experienced double-digit revenue growth across all sectors, driven by robust performance in consumables and capital equipment. Due to strong orders and year-to-date performance, Repligen has raised its full-year revenue guidance. The company continues to focus on bioprocessing technology.
Read more →RGEN▼ -5.9%on this newsshared move
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance • Revenue of $189 millio
Repligen Corporation reported its third quarter 2025 financial results, demonstrating strong growth with a 22% year-over-year increase in revenue. The company's revenue for the quarter reached $189 million and it raised its full-year financial guidance to between $729 to $737 million. Noteworthy growth was observed across all franchises, with particular strength in consumables and capital equipment. The launch of the SoloVPE PLUS technology and a partnership with Novasign to integrate digital twin capabilities were highlighted as key business developments.
Read more →RGENRepligen to Report Third Quarter 2025 Financial Results
Repligen Corporation will announce its third quarter 2025 financial results on October 28, 2025. A press release will precede the market opening, followed by a conference call at 8:30 a.m. ET to discuss the results. The call will be accessible to both domestic and international callers, and a webcast will also be available.
Read more →RGENRepligen Corporation to Present at Upcoming September Conferences
Repligen Corporation announced its participation in three major upcoming investor conferences, including the Wells Fargo Healthcare Conference, Deutsche Bank Healthcare Summit, and Bank of America Global Healthcare Conference. Key executives will lead discussions and meetings at these events, which aim to showcase the company's advancements in bioprocessing technology. Webcasts of the presentations will be available for investors to access and review at their convenience.
Read more →RGENRepligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
Repligen Corporation has announced a strategic partnership with Novasign to integrate advanced machine learning and modeling workflows into its filtration systems. This collaboration aims to enhance Repligen's digitalization efforts and improve process analytical technology. The partnership is expected to lead to smarter process development, real-time predictive control, and reduced costs and timelines in bioprocessing.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2025 Financial Results • Revenue of $182 million, year-over-year increase of 15% as reported
Repligen Corporation reported its financial results for the second quarter of 2025, revealing a revenue of $182 million, marking a 15% increase year-over-year, with a notable 17% organic non-COVID growth. CEO Olivier Loeillot highlighted the momentum across their product portfolio, including significant growth in consumables and capital equipment. The company's revenue guidance for the full fiscal year has been raised to a range of $715 to $735 million, reflecting optimism despite challenges from new modalities. The financial results indicate strong demand in the biopharma sector, with all business segments showing growth.
Read more →RGENRepligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Repligen Corporation reported its second quarter 2025 financial results, showcasing a revenue increase of 15% year-over-year, reaching $182 million. The company noted significant growth in orders, exceeding 20% year-over-year, and raised its revenue guidance for the full year 2025 to a range of $715 to $735 million, reflecting expected organic growth. Optimism was expressed by management, citing continued strong performance across its product portfolio despite some short-term headwinds. The company also highlighted the launch of new products and a commitment to sustainability initiatives.
Read more →RGENRepligen to Report Second Quarter 2025 Financial Results
Repligen Corporation is set to report its second quarter 2025 financial results on July 29, 2025. A press release will be issued before market opening, followed by a conference call at 8:30 a.m. ET. The call will provide updates on business and financial performance for the three- and six-month periods ending June 30, 2025. The event will also be available via webcast and archiving for replay.
Read more →RGENRepligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
Repligen Corporation has published its 2024 Corporate Sustainability Report, themed 'Perspectives on Progress.' The report outlines the company's advancements in sustainability across six key areas and aligns with the UN Sustainable Development Goals. CEO Olivier Loeillot emphasized the importance of sustainability for business resilience, while VP Dianne Heiler highlighted the commitment to creating business value through sustainable practices.
Read more →RGENRepligen Corporation to Present at William Blair Growth Conference
Repligen Corporation will participate in the William Blair 45th Annual Growth Stock Conference from June 3-5, 2025. CEO Olivier Loeillot is scheduled to present on June 3 at 1:20 p.m. CT. A live webcast of the presentation will be available on the company's Investor Relations website.
Read more →RGENRepligen Corporation to Present at Upcoming May Investor Conferences
Repligen Corporation announced its participation in several investor conferences in May. The company will provide a live webcast of its presentation at the RBC conference, which will also be available for replay. Repligen focuses on innovative bioprocessing technologies that enhance the manufacturing of biological drugs.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2025 Financial Results • Revenue of $169 million, year-over-year increase of 10% as reported
Repligen Corporation reported financial results for Q1 2025, showing a revenue of $169 million, which is a 10% increase year-over-year. The company also noted a significant adjusted operating income rise of 72%, alongside a nearly 20% increase in total orders. Repligen reaffirms its full-year organic revenue guidance between 9.5% and 13.5%, suggesting sustained confidence in their operational outlook. The company further bolstered its analytics capabilities through the acquisition of 908 Devices' bioprocessing portfolio.
Read more →RGENRepligen Reports First Quarter 2025 Financial Results
Repligen Corporation (NASDAQ:RGEN) reported its first quarter 2025 financial results, highlighting a revenue of $169 million, which is a 10% increase from the previous year. The company achieved a significant improvement in adjusted operating income, up 72% year-over-year. Orders have also shown robust growth, increasing nearly 20%, which reflects positive momentum across all franchises. Repligen reiterated its full-year 2025 organic revenue guidance and discussed its recent acquisition aimed at enhancing its bioprocessing technology offerings.
Read more →RGENRepligen to Report First Quarter 2025 Financial Results
Repligen Corporation announced the schedule for its first quarter 2025 financial results, which will be reported on April 29, 2025. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. ET to discuss the results and business updates. The call will be accessible to domestic and international callers, with options for a webcast and archived replay available.
Read more →RGEN▼ -6.2%on this news
Repligen Appoints Jacob Johnson As Vice President Investor Relations
Repligen Corporation has appointed Jacob Johnson as Vice President of Investor Relations to enhance its engagement with the investment community. Mr. Johnson, previously a Managing Director at Stephens Inc., possesses extensive knowledge in the life sciences tools sector, which is expected to benefit Repligen. The company acknowledged the contributions of outgoing VP Sondra Newman, who is retiring after a significant tenure since 2012.
Read more →RGENRepligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Repligen Corporation has acquired a bioprocessing analytics portfolio from 908 Devices for $70 million in cash. This acquisition includes four desktop devices designed for process analytical technology applications, enhancing Repligen's capabilities in optimizing biopharmaceutical development processes. Both companies' leaders expressed optimism about the synergy created by this transaction, paving the way for further innovations in the field. The deal positions Repligen to offer comprehensive analytics solutions across the entire bioprocess workflow.
Read more →RGEN▲ +7.9%on this news
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2024 Financial Results • Fourth quarter revenue of $168 million and full year
Repligen Corporation reported strong financial results for Q4 and the full year 2024, with Q4 revenues rising to $168 million and full year revenues reaching $634 million. The company experienced significant growth in orders and has set optimistic guidance for 2025, expecting reported growth of 8% to 12%. While Repligen's operational losses have increased, particularly in GAAP measures, it remains confident in its business strategy, highlighted by successful acquisitions and innovative product launches.
Read more →RGEN▲ +7.9%on this news
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Repligen Corporation (NASDAQ:RGEN) reported fourth quarter revenues of $168 million and full year revenues of $634 million for 2024. The company experienced an 11% sequential increase in orders and an 8% rise in revenues during the fourth quarter. Repligen is optimistic about continuing growth into fiscal year 2025, providing guidance for reported revenue growth of 8% to 12%. However, the company also reported a GAAP loss of $(37) million in operations for the fourth quarter, indicating challenges despite overall positive performance.
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2024 Financial Results
Repligen Corporation has announced the scheduled reporting of its fourth quarter and full year 2024 financial results. The announcement includes a press release set to be issued before market opening on February 20, 2025, followed by a conference call to discuss the results and business updates. This event emphasizes Repligen's commitment to transparency and engagement with its investors.
Read more →RGENRepligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
Repligen Corporation has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16 in San Francisco. The company's CEO, Olivier Loeillot, will deliver a presentation on January 14 at 1:30 p.m. PT, providing an overview of the company. A live webcast of the event will be available via Repligen's Investor Relations website, and a replay will be offered for a limited time post-event.
Read more →RGENRepligen Launches the CTech™ SoloVPE PLUS System
Repligen Corporation has launched its CTech™ SoloVPE® PLUS System, aimed at improving UV-based concentration measurement for biopharmaceutical manufacturers. This system enhances accuracy, speed, and usability in complex production processes, addressing the industry's shift toward higher drug concentrations. It offers multiple advantages, such as a streamlined workflow and doubled data acquisition speed, thereby supporting better decision-making and productivity. This launch marks a significant advancement in Repligen's analytical technology portfolio, with more products expected in 2025.
Read more →RGENRepligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
Repligen Corporation announced the digital publication of its 2023 Corporate Sustainability Report, highlighting advancements in various sustainability metrics. The report emphasizes the company's commitment to responsible practices across six impact areas, including products, operations, and community engagement. Notable achievements include a transition to 100% renewable electricity at a majority of manufacturing sites and a significant reduction in emissions. The report aligns with several key sustainability reporting frameworks, demonstrating Repligen's ongoing dedication to environmental stewardship and corporate responsibility.
Read more →RGENRepligen Launches Novel AVIPure dsRNA Resin in OPUS Pre-packed Columns
Repligen Corporation has launched the AVIPure dsRNA Clear OPUS columns, designed to improve the purification process of mRNA therapeutics and vaccines. This new product combines advanced affinity chromatography technology to effectively remove dsRNA impurities, enhancing overall drug efficacy. The launch is a strategic move following Repligen's recent acquisition of Tantti Laboratory Inc. and emphasizes the company's commitment to innovation in bioprocessing solutions.
Read more →RGEN▲ +6.5%on this news
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2024 Financial Results Third quarter reported revenue of $155 million, an increase of 10% year-over-
Repligen Corporation reported a 10% increase in revenue for the third quarter of 2024, totaling $155 million. The company's strong results were attributed to better market conditions and improved sales across Contract Development and Manufacturing Organizations (CDMO) and new modalities. Repligen has also narrowed its full-year revenue guidance, maintaining optimism for growth moving into 2025. However, the company faced challenges with a negative operating margin of (5.1%) in the same quarter.
Read more →RGEN▲ +6.5%on this news
Repligen Reports Third Quarter 2024 Financial Results
Repligen Corporation has announced its financial results for the third quarter of 2024, displaying a revenue increase of 10% year-over-year to $155 million. The company's CDMO revenue and orders show promising growth of around 20%. Moreover, Repligen is optimistic about its full-year guidance, which has been narrowed to a range of $630-$639 million. Despite a reported net loss and decreased operating margins, the overall performance reflects positive momentum in their business sectors.
Read more →RGENRepligen Corporation to Present at Upcoming Investor Conferences
Repligen Corporation has announced its participation in three upcoming investor conferences. The events include the UBS Global Healthcare Conference, the Stifel Healthcare Conference, and the Stephens Annual Investment Conference, scheduled between November 11 and November 21, 2024. Key executives, including the CEO and CFO, will engage in analyst-led discussions, providing a platform to showcase their bioprocessing technology leadership.
Read more →RGENRepligen to Report Third Quarter 2024 Financial Results
Repligen Corporation will announce its third quarter 2024 financial results on November 12, 2024, following necessary revenue restatements disclosed earlier. CEO Olivier Loeillot emphasized the team's efforts to finalize the changes and prepare for the upcoming call set for 8:30 a.m. ET. The event will include updates on business performance and be accessible via both a conference call and a webcast.
Read more →RGENRepligen Opens Training & Innovation Center to Elevate Customer Experience
Repligen Corporation has opened the Repligen Training & Innovation Center in Waltham, aimed at elevating customer experiences through interactive engagement with their bioprocessing technologies. The facility features product exhibits and training areas designed to support customers pre- and post-sales. This initiative complements their ongoing expansion efforts, including a new site in Estonia, positioning Repligen for growth in the biologics sector. CEO Olivier Loeillot emphasized the company's commitment to innovation and customer satisfaction.
Read more →RGENSafe Harbor This report contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not desc
Regeneron Pharmaceuticals (RGEN) announced the need for a restatement of its financials for 2023 and the first half of 2024 due to adjustments in revenue recognition of a COVID-related cancellation fee. The company reassured stakeholders that overall business operations remain unaffected and reaffirmed its revenue guidance for 2024. However, risks were identified concerning internal control effectiveness and completing the financial restatements, which may lead to increased scrutiny and potential delays. Investors are cautioned against relying on prior financial communications that may no longer be valid.
Read more →RGENRepligen Corporation to Present at Wells Fargo Healthcare Conference
Repligen Corporation (RGEN) will present at the Wells Fargo Healthcare Conference taking place from September 4-6, 2024, in Boston. CEO Olivier Loeillot will be involved in an analyst-led discussion on September 6 at 8:45 a.m. ET. A live webcast of the presentation will be available, providing an opportunity for both live viewing and later replay. This participation underscores the company's commitment to engaging with investors and showcasing its bioprocessing technology advancements.
Read more →RGEN▲ +16.4%on this news
Repligen Reports Second Quarter 2024 Financial Results
Repligen Corporation (NASDAQ:RGEN) reported its second quarter financial results for 2024, with revenues of $154 million and orders amounting to $157 million. The company noted a slight decrease in GAAP net income compared to the same quarter last year but expressed confidence in achieving above-industry growth in the latter half of 2024. Key highlights included the transition of leadership with a new CEO taking over in September and a strategic acquisition aimed at bolstering its chromatography segments. Although revenue guidance was narrowed due to market conditions in China, overall performance remains aligned with company expectations.
Read more →RGEN▲ +16.4%on this news
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2024 Financial Results Reports second quarter revenue of $154 million Second quarter orders of $157
Repligen Corporation announced its financial results for the second quarter of 2024, reporting revenues of $154 million and an overall strong performance driven by demand in the pharmaceutical sector. The company projected a positive outlook for the remainder of the year, despite potential challenges stemming from reduced orders in China. Management highlighted the strength of new product launches and strategic acquisitions. However, they also noted a slight decrease in margins compared to the previous year, prompting a revision of revenue guidance.
Read more →RGENRepligen Announces Agreement to Acquire Chromatography Innovator Tantti
Repligen Corporation announced its agreement to acquire Tantti Laboratory Inc., a company specializing in chromatography bead technology for bioprocess applications. This acquisition is expected to enhance Repligen’s capabilities in purifying new modalities such as viral vectors and nucleic acids. The DuloCore technology from Tantti offers high efficiency, aligning with Repligen’s existing product lines. Completion of the transaction is anticipated by the end of 2024 and aims to provide both breakeven and eventually accretive earnings to Repligen.
Read more →RGEN▲ +10.1%on this news
Repligen to Report Second Quarter 2024 Financial Results
Repligen Corporation has announced that it will report its second quarter 2024 financial results on July 30, 2024. A press release will be issued prior to market opening, and a conference call will be held at 8:30 a.m. ET to discuss the financial outcomes of the reporting period ended June 30, 2024. The call will be accessible via phone and webcast, with options for replay for those who cannot attend live.
Read more →RGEN▼ -11.8%on this news
Repligen Announces CEO Transition Plan
Repligen Corporation announced a leadership transition plan, with Tony J. Hunt moving from CEO to Executive Chair effective September 1, 2024. Olivier Loeillot, currently the President and Chief Commercial Officer, will take over as President and CEO on the same date. Hunt has led the company since 2015, achieving substantial growth, while Loeillot is expected to continue this trajectory using his extensive industry experience. The transition reflects a strategic plan developed by the Board to ensure the company's continued success and innovation.
Read more →RGEN▼ -11.8%on this news
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN ANNOUNCES CEO TRANSITION PLAN Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot
Repligen Corporation announced a leadership transition plan, effective September 1, 2024, where Tony J. Hunt will move from CEO to Executive Chair, and Olivier Loeillot will assume the role of President and CEO. Hunt, who has led the company since 2015, has significantly contributed to its growth, increasing revenue from around $63 million to $639 million. The Board believes that Loeillot, who has been with Repligen since October 2023, is well-suited to build on Hunt's legacy and lead the company through its next growth phase. The transition is a strategic decision aimed at ensuring the company's ongoing success and innovation.
Read more →RGENRepligen Corporation to Present at Upcoming June Investor Conferences
Repligen Corporation (NASDAQ:RGEN) has announced its participation in upcoming investor conferences in June 2024. CEO Tony J. Hunt will present at the William Blair's 44th Annual Growth Stock Conference, and other executives will engage in discussions at Jefferies' Global Healthcare Conference. The events are designed to enhance investor communication and showcase the company's bioprocessing technology leadership. Attendees can access the presentations via a live webcast on Repligen's Investor Relations website.
Read more →RGENRepligen Reports First Quarter 2024 Financial Results
Repligen Corporation (NASDAQ:RGEN) reported its first quarter 2024 financial results, announcing a revenue of $151 million, down from $182.7 million in the prior year. The company noted a significant reduction in GAAP net income to $2.1 million, partly due to reduced COVID-related revenue. Despite these challenges, Repligen's new modalities revenue grew by 16% year-over-year, and the company maintained its financial guidance for the full year 2024. CEO Tony J. Hunt expressed optimism about services to new modality customers and ongoing growth from recent acquisitions.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2024 Financial Results Reports first quarter revenue of $151 million Increased new modalities revenu
Repligen Corporation announced its financial results for Q1 2024, reporting a revenue of $151 million, in line with its sales target for the first half of the year. The company reaffirmed its financial guidance for the full year while indicating a slight market recovery reflected in its book-to-bill ratio of 0.99. Though the Filtration franchise experienced growth, margins have decreased compared to the previous year. Overall, despite challenges in profitability, the company demonstrates confidence in its business outlook and continued investments in new modalities.
Read more →RGENRepligen to Report First Quarter 2024 Financial Results
Repligen Corporation announced that it will report its first quarter 2024 financial results on May 1, 2024. The company will issue a press release before the market opens and hold a conference call at 8:30 a.m. ET to discuss the results for the three-month period ending March 31, 2024. The call will be accessible to both domestic and international callers, and a webcast will also be available on their Investor Relations website.
Read more →RGENRepligen Appoints Maggie A. Pax to Board of Directors
Repligen Corporation announced the appointment of Maggie A. Pax to its Board of Directors, expanding the board from eight to nine members. With over 25 years of experience in the life sciences sector, Ms. Pax previously served in leadership roles at Thermo Fisher Scientific, guiding growth strategies and innovations. Repligen's leadership expressed confidence in her ability to contribute to key focus areas, such as strategic partnerships and continuous innovation. Her extensive background and achievements position her as a valuable addition to the team.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Maggie A. Pax to Board of Directors WALTHAM, MA
Repligen Corporation has appointed Maggie A. Pax to its Board of Directors, expanding the board from eight to nine members. Ms. Pax has over 25 years of experience in the life sciences sector, including key leadership roles at Thermo Fisher Scientific. Her expertise in strategic planning and innovation is expected to enhance Repligen's growth initiatives. The leadership views her appointment as beneficial for guiding strategic change and fostering partnerships in the bioprocessing industry.
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2023 Financial Results
Repligen Corporation reported its financial results for the fourth quarter and full year 2023, showing fourth quarter revenue of $156 million and total revenue for the year at $639 million. The company demonstrated order strength with a book-to-bill ratio of 1.03 for the quarter and solid growth in its Filtration and Analytics franchises. However, the company also faced challenges, including a significant decline in net income and gross profit margins compared to the previous year. Looking ahead, Repligen provided guidance anticipating revenues in 2024 between $620 million and $650 million, with a focus on recovering from current market headwinds.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2023 Financial Results Reports fourth quarter revenue of $156 million and full year r
Repligen Corporation announced its fourth quarter and full year 2023 financial results, reporting a quarter revenue of $156 million. Total revenue for 2023 decreased to $638.8 million compared to $801.5 million in 2022. The company highlighted a strong order intake, especially in their Filtration and Analytics divisions, and expressed optimism for improved market conditions in 2024. Despite these positive notes, the company faced significant declines in gross profit and net income year-over-year.
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2023 Financial Results
Repligen Corporation has announced that it will report its fourth quarter 2023 financial results on February 21, 2024. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. ET to discuss the results and business updates. Investors can access the conference call via a toll-free line or through a webcast on the company's website, with both options archived for later listening.
Read more →RGENRepligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
Repligen Corporation, targeting bioprocessing technology, announced its presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Tony J. Hunt will present on January 9, 2024, sharing insights into the company. A live webcast will be available on Repligen's Investor Relations website, emphasizing accessibility. This event signifies the company's proactive engagement in the biopharma industry.
Read more →RGENRepligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
Repligen Corporation announced a private transaction to issue $600 million in new 1.00% convertible senior notes due 2028. This includes exchanging $309.9 million of existing 2024 notes and obtaining new cash subscriptions. The proceeds are expected to bolster their balance sheet, fund share repurchases, and potentially finance acquisitions or investments, although no immediate plans exist for acquisitions. The deal will reduce the outstanding 2024 notes to $69.7 million. The company's guidance for year-end cash and cash equivalents has been significantly raised as a result of this transaction.
Read more →RGENExecution Version
Repligen Corporation is offering a new series of Convertible Senior Notes due 2028, providing existing investors an opportunity to exchange their old notes. The firm plans to execute these transactions in accordance with specific terms detailed in an Exchange/Subscription Agreement. The new notes may be converted into cash or common stock, reflecting potential advantages in financing. The exchange process is scheduled to occur on December 14, 2023.
Read more →RGENRepligen Launches TangenX SC as First-to-Market Holder-Free Self-Contained TFF Device
Repligen Corporation has launched TangenX® SC, a groundbreaking holder-free, self-contained Tangential Flow Filtration (TFF) device. This innovative technology aims to enhance the efficiency of biopharmaceutical manufacturing, especially for biologics like antibody drug conjugates and viral vectors. Key advantages of TangenX SC include a significant reduction in setup time, improved safety for operators, and a design that minimizes product loss. This advancement represents a substantial leap in TFF technology for purification processes integral to drug production.
Read more →RGEN▲ +17.9%on this news· ran to +32% by day 3shared move
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance Reports total third quarter rev
Repligen Corporation reported its financial results for Q3 2023, revealing a significant decrease in total revenue compared to the same quarter last year. Despite the overall decline, the company noted positive trends, including a stronger order book and a rebound in Pharma orders. The CEO expressed cautious optimism regarding future growth, particularly in the gene therapy sector. The financial guidance for the full year remains unchanged, anticipating continued challenges but also potential recovery in key areas of their business.
Read more →RGEN▲ +17.9%on this news· ran to +32% by day 3shared move
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
Repligen Corporation has reported its third quarter financial results for 2023, revealing total revenues of $141.2 million, a decrease from $200.7 million in Q3 2022. The company noted a strengthening order book with a book-to-bill ratio of 1.07 and a rebound in orders from its pharmaceutical client base. Despite these positive signs, Repligen has faced revenue declines and significant restructuring costs, prompting a revision of its full-year revenue guidance. The acquisition of Metenova AB is expected to enhance its fluid management capabilities further.
Read more →RGENRepligen to Report Third Quarter 2023 Financial Results
Repligen Corporation will report its third quarter 2023 financial results on October 31, 2023. A press release will precede the market opening, followed by a conference call at 8:30 a.m. ET. The call will cover business updates and results for the three- and nine-month periods ending September 30, 2023. Both a live and an archived version of the call will be made available for investors.
Read more →RGENRepligen Appoints Olivier Loeillot as President and Chief Commercial Officer
Repligen Corporation has appointed Olivier Loeillot as President and Chief Commercial Officer effective immediately. Loeillot brings over 20 years of experience, having held significant roles in companies such as Cytiva and GE Healthcare Life Sciences. His responsibilities at Repligen will include overseeing all business units and driving the company's commercial strategies. The CEO of Repligen expressed confidence that Loeillot's extensive background will facilitate the company's growth in the bioprocessing market.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453
Repligen Corporation has appointed Olivier Loeillot as the new President and Chief Commercial Officer, effective immediately. With over 20 years of industry experience, including roles at Cytiva and GE Healthcare Life Sciences, Loeillot is expected to leverage his expertise to enhance Repligen's commercial strategies and business units. CEO Tony J. Hunt expressed enthusiasm about Loeillot's appointment, highlighting its potential to propel the company towards significant growth in the bioprocessing market.
Read more →RGENRepligen Announces Agreement to Acquire Fluid Management Innovator Metenova
Repligen Corporation has announced a definitive agreement to acquire Metenova AB, a leading innovator in magnetic mixing technologies, for $24 to $25 million in revenue. This acquisition is expected to enhance Repligen's Fluid Management portfolio and contribute significant revenue growth over the next few years. The deal is anticipated to be accretive to Repligen’s earnings starting in 2025, with plans for rapid expansion in the single-use market. Repligen will fund the acquisition through a combination of cash and equity.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE FLUID MANAGEMENT INNOVATOR METENOVA Proposed acquisition adds market leading magnetic mixin
Repligen Corporation has announced a definitive agreement to acquire Metenova AB, a Swedish innovator in fluid management technologies, particularly magnetic mixing solutions. This acquisition is projected to generate significant revenue growth for Repligen, with estimates of approximately $25 million in 2024 and continued growth thereafter. The deal is expected to be accretive to Repligen’s margins and earnings in the coming years and enhances their portfolio in the rapidly expanding single-use market. The transaction is pending customary closing conditions and will be financed through a mix of cash and equity.
Read more →RGENRepligen Appoints Jason K. Garland as Chief Financial Officer
Repligen Corporation has appointed Jason K. Garland as Chief Financial Officer, effective September 25, 2023, succeeding retiring CFO Jon K. Snodgres. Garland brings extensive experience, having served as CFO at Integer Holdings and held senior roles at General Electric. The leadership change is aimed at driving financial and operational performance as the company continues to focus on growth and innovations in bioprocessing. Snodgres will assist Garland during the transition period to ensure a smooth handover.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance Reports second quarter revenue
Repligen Corporation reported its second quarter financial results for 2023, indicating a challenging environment for bioprocessing. The company noted a decline in base revenues, primarily impacted by a significant drop in the Filtration sector. Despite maintaining growth in the Analytics, Proteins, and Chromatography franchises, the overall financial outlook for the year has been adjusted to reflect expectations of a 7% decline in base business revenue. The company remains optimistic about managing these headwinds and sees a potential increase in orders in the forthcoming quarter.
Read more →RGENRepligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
Repligen Corporation reported its second quarter financial results, revealing total revenue of $159.2 million, a decline of 23.3% compared to the previous year. The company has adjusted its full-year revenue guidance to a range of $635-$665 million, significantly lower than prior forecasts. Although certain segments, notably Cell & Gene Therapy, showed growth, the overall performance is affected by challenges in the Filtration area. Management remains cautiously optimistic about future recovery, expecting improvement in orders by the fourth quarter.
Read more →RGENRepligen to Report Second Quarter 2023 Financial Results
Repligen Corporation announced that it will release its financial results for the second quarter of 2023 on August 2, 2023. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. ET to discuss the results and business updates. The call will be accessible via phone and webcast, with archival options for later viewing. Investors are reminded that some statements in the announcement may be forward-looking and subject to risks.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance Reports first quarter revenue o
Repligen Corporation reported its Q1 2023 financial results, highlighting a 7% year-over-year growth in its base business, driven by strong performances in its Chromatography and Proteins franchises. The company also announced an acquisition of FlexBiosys to strengthen its Fluid Management portfolio. Despite these positive developments, Repligen anticipates challenges for the remainder of 2023 due to a projected slowdown in order growth and a decrease in COVID-related revenue affecting its Filtration segment. The revised guidance for 2023 indicates expected base business growth of 4% to 8%.
Read more →RGENRepligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basis Closed on acquisition of single-use bag manufacturer FlexBiosys Inc. i
Read more →RGENRepligen to Report First Quarter 2023 Financial Results
Repligen Corporation has announced that it will report its first quarter 2023 financial results on May 2, 2023. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. ET to discuss the financial results and business updates. The conference call will be accessible to both domestic and international audiences, and both the call and its webcast will be archived for future access.
Read more →RGEN▲ +5.5%on this news
Repligen to Acquire FlexBiosys Inc.
Repligen has announced the acquisition of FlexBiosys Inc., aiming to enhance its Fluid Management capabilities and expand its market reach. This strategic acquisition is expected to accelerate revenue growth, with predictions of a 25% annual increase beginning in 2024. Additionally, Repligen plans to leverage FlexBiosys's manufacturing capabilities to strengthen its position in single-use bag markets. As part of the acquisition, Repligen will integrate FlexBiosys's operations, contributing an estimated $5M-$6M in revenue for the current fiscal year.
Read more →RGENRepligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2022 Financial Results Fourth quarter revenue of $186.8 million represents year-over-
Repligen Corporation reported strong financial results for Q4 and the full year of 2022, achieving a revenue of $186.8 million in the fourth quarter and over $800 million for the year. The company experienced a 35% organic growth in the last quarter and a total growth of 25% for the year. With significant product innovation, including ten new launches, Repligen aims for continued organic growth of 12%-16% in 2023. The performance solidifies the company's leadership in bioprocessing technologies.
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2022 Financial Results
Fourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currency Full year revenue of $801.5 million represents year-over-year organic growth of 22% and 25% growth at constant currency Base business organic growth was 35
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Martin D. Madaus to Board of Directors WALTHAM, MA
Repligen Corporation has appointed Martin D. Madaus to its Board of Directors, bringing over 25 years of experience in the life sciences tools sector. Madaus is recognized for his previous role as CEO of Millipore Corporation and his current positions on the boards of several public and private companies. Key figures at Repligen, including Chairperson Karen A. Dawes and CEO Tony J. Hunt, have expressed strong confidence in his ability to drive growth and transformation in bioprocessing. This appointment is positioned as a strategic move to enhance Repligen's market presence and technological innovation.
Read more →RGENRepligen Appoints Martin D. Madaus to Board of Directors
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the Repligen board over 25 years of industry experience, i
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2022 Financial Results
WALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, 2023. The Company will issue a press release before the market open
Read more →RGENRepligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41st Annual J.P. Morgan Healthcare conference being held January 9-12 in San F
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance Reports revenue of $200.7 milli
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance WALTHAM, Mass. November 1, 2022 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for
Read more →RGENRepligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agreement WAL
Read more →RGENRepligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (“Purolite”), for the development and manufacturing of affinity ligands focused on monoclonal
Read more →RGENRepligen to Report Third Quarter 2022 Financial Results
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2022 financial results on Tuesday, November 1, 2022. The Company will issue a press release before the market opens and will host a
Read more →RGENRepligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
WALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions t
Read more →RGENRepligen To Host Investor Day 2022
WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the Na
Read more →RGEN▲ +11.7%on this news
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance Record revenue of $207.6 millio
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance WALTHAM, Mass. August 02, 2022 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for i
Read more →RGEN▲ +11.7%on this news
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year) Strong organic revenue growth of 29% and strong base business growth of 41% for the quarter Revenue guidance raised to $790 - $810 mill
Read more →RGENRepligen to Report Second Quarter 2022 Financial Results
WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2022 financial results on Tuesday, August 2, 2022. The Company will issue a press release before the market opens and will host a c
Read more →RGENRepligen Appoints Dr. Konstantin Konstantinov to Board of Directors
WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov brings to the director role nearly
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors WALTHAM, MA
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors WALTHAM, MA May 26, 2022 Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Ko
Read more →RGEN▲ +10.5%on this news
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related dem
Read more →RGEN▲ +10.5%on this news
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance Record revenue of $206.4 millio
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance WALTHAM, Mass. April 27, 2022 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for it
Read more →RGENRepligen to Report First Quarter 2022 Financial Results
WALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27, 2022. The Company will issue a press release before the market opens and will host a
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2021 Financial Results
— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% — Record revenue of $670.5 million for the year, and year-over-year growth of 83% — Organic revenue growth of 69% for the fourth quarter and 71% for the year 2021 — Completes acquisition of si
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2021 Financial Results Record revenue of $186.5 million for the quarter, and year-ove
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results WALTHAM, Mass. Feb. 17, 2022 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 20
Read more →RGENRepligen Launches AAV Affinity Resins for Gene Therapy Purification
WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of three advanced affinity chromatography resins for use in gene therapy manufacturi
Read more →RGENRepligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11th Annual SVB Leerink Healthcare Conference being held Feb. 14-18,
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2021 Financial Results
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022. The Company will issue a press release before the market opens
Read more →RGENRepligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-
Read more →RGENRepligen Acquistion of BioFlex Solutions*
*Acquisition of BioFlex Solutions, LLC includes the company's manufacturing arm, Newton T&M Safe Harbor This presentation contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this presentation which ar
Read more →RGENRepligen Releases Inaugural Sustainability Report
WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Company’s website. Repligen’s 2020 Sustainability Report provides an overview of the Company’s environmental, social and gove
Read more →RGEN▲ +7%on this news
Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77% Raises revenue guidance to $655-$665 million for full year 2021 Completes acquisition of affinity ligands innovator Avitide Inc. WALTHAM, Mass., Oct. 2
Read more →RGEN▲ +7%on this news
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance Reports record revenue of $178.
Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance WALTHAM, Mass. October 28, 2021 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for
Read more →RGEN▲ +6.1%on this news
Repligen to Report Third Quarter 2021 Financial Results
Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2021 financial results on Thursday, October 28,
Read more →RGENRepligen Announces Agreement to Acquire Avitide Inc.
Proposed acquisition strengthens Repligen’s Proteins business Adds a market leader in affinity ligand discovery and development and complements established partnership with Navigo GmbH Strategically moves Repligen into affinity resin solutions for gene therapy Avitide is expec
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Announces Agreement to Acquire Avitide Inc. Proposed acquisition strengthens Repligen s Proteins business Adds a market le
Repligen Announces Agreement to Acquire Avitide Inc. WALTHAM, MA September 16, 2021 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-h
Read more →RGENRepligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), today announced they have completed development and validation of a novel protein A
Read more →RGEN▲ +9.9%on this news
Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Reported revenue was $163.0 million for the quarter, representing year-over-year growth of 86% and organic growth of 69% Revenue guidance raised to $625-$645 million for full year 2021 Acquisition of hollow fiber innovator Polymem S.A. completed July 1, 2021 WALTHAM, Mass., Ju
Read more →RGEN▲ +9.9%on this news
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance Reported revenue was $163.0 mi
Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance WALTHAM, Mass. July 27, 2021 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for it
Read more →RGENRepligen to Report Second Quarter 2021 Financial Results
WALTHAM, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2021 financial results on Tuesday, July 27, 2021. The Company will issue a press release before the market opens and will host a co
Read more →RGENRepligen Corporation Announces Agreement to Acquire Polymem S.A.
WALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Toulouse, France based Polymem S.A. (“Polymem”), a leadin
Read more →RGENRepligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69% Growth driven by combination of COVID-related demand, base business strength and acquisition revenue WALTHAM, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Replig
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance Reported revenue was $142.8 mil
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2021 and Updates Full Year 2021 Financial Guidance WALTHAM, Mass. May 4, 2021 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bio
Read more →RGENRepligen to Report First Quarter 2021 Financial Results
WALTHAM, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021. The Company will issue a press release before the market opens and will host a conf
Read more →RGENRepligen Corporation to Present at Barclays Global Healthcare Conference
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Sn
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2020 Financial Results
Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growth Organic revenue growth was 47% for the fourth quarter and 29% for the year 2020 WALTHAM, Mass., Feb. 24, 2021 (GLOBE NE
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2020 Financial Results Reports quarterly revenue of $108.6 million, representing 56%
Repligen Reports Fourth Quarter and Full Year 2020 Financial Results WALTHAM, Mass. Feb. 24, 2021 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 20
Read more →RGENRepligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2020 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2020 financial results on Wedne
Read more →RGENRepligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in nove
Read more →RGENRepligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 39th Annual J.P. Morgan Healthcare conference being held January 11-
Read more →RGENRepligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters’ Option
WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 million shares of its common stock at a public offering price of $181 per share for
Read more →RGENRepligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public offering price of $181 per share. In addition, Repligen Corporation has grant
Read more →RGENRepligen Corporation Announces Proposed Public Offering of Shares of Common Stock
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day opti
Read more →RGENSource: Repligen Corporation
Source: Repligen Corporation December 7, 2020 07:22 ET Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock WALTHAM, Mass., December 7, 2020 (GLOBE NEWSWIRE) Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritte
Read more →RGENRepligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $94.1 million with strong margin expansion Overall revenue grew 35% year-over-year, with organic growth of 31% Raises revenue guidance to $348-$352 million and overall revenue growth to 29%-30% for full year 2020, representing 23%-24% organic
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance Reports record quarterly revenu
Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance WALTHAM, Mass. November 5, 2020 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for
Read more →RGENRepligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
Proposed ARTeSYN acquisition adds gold standard single-use downstream bioprocessing systems Advances Repligen’s Systems strategy in Filtration and Chromatography, complementing TangenX® Flat Sheet cassettes and OPUS® PPC Completes acquisition of Non-Metallic Solutions (NMS), co
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions WALTHAM, MA, October 27, 2020 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology
Read more →RGENRepligen to Report Third Quarter 2020 Financial Results
- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST - WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2020 financial results on Thursday, November
Read more →RGENRepligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines
WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in nove
Read more →RGENRepligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $87.5 million Overall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth Completes acquisition of silicone molding and tubing manuf
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance Reports record quarterly reven
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance WALTHAM, Mass. July 30, 2020 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for it
Read more →RGENRepligen to Report Second Quarter 2020 Financial Results
WALTHAM, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2020 financial results on Thursday, July 30, 2020. The Company will issue a press release before the market opens and will host a c
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Announces Agreement to Acquire Engineered Molding Technology Expands Single-Use Portfolio with Expertise in Silicone Moldi
Repligen Announces Agreement to Acquire Engineered Molding Technology Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing WALTHAM, MA June 29, 2020 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership
Read more →RGENRepligen Announces Agreement to Acquire Engineered Molding Technology
WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Albany, New York based Engineered Molding Technology (“EM
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Carrie Eglinton Manner to Board of Directors WALTHAM, MA
Repligen Appoints Carrie Eglinton Manner to Board of Directors WALTHAM, MA June 15, 2020 Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors. Ms. Eglinton Manner brings to the direc
Read more →RGENRepligen Appoints Carrie Eglinton Manner to Board of Directors
WALTHAM, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors. Ms. Eglinton Manner brings to the director role over 23 years of leadership expe
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance Reports record quarterly revenu
Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance WALTHAM, Mass. May 6, 2020 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f
Read more →RGENRepligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $76.1 million Overall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through first four months WALTHAM, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focuse
Read more →RGENRepligen to Report First Quarter 2020 Financial Results
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2020 financial results on Wednesday, May 6, 2020. The Company will issue a press release before the market opens and will host a co
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors WALTHAM, MA
Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors WALTHAM, MA February 27, 2020 Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings to the director rol
Read more →RGENRepligen Appoints Rohin Mhatre, Ph.D. to Board of Directors
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings to the director role over 25 years of relevant experience, wh
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2019 Financial Results Reports quarterly revenue of $69.5 million, representing 34% y
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2019 Financial Results WALTHAM, Mass. Feb. 20, 2020 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2019 Financial Results
Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growth Overall organic revenue growth was 21% for the fourth quarter and 33% for the year 2019 WALTHAM, Mass., Feb. 20, 2020 (G
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2019 Financial Results
WALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday, February 20, 2020. The Company will issue a press release before the market opens
Read more →RGENRepligen to Present at the 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will present at the 38th annual J.P. Morgan Healthcare Conference, to be held at the West
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance Reports quarterly revenue of $6
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance October 31, 2019 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarte
Read more →RGENRepligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year Raises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Repligen Cor
Read more →RGENRepligen to Report Third Quarter 2019 Financial Results
WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The Company will issue a press release before the market opens and will host a
Read more →RGENRepligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 million for full year 2019, representing 29%-31% organic growth Completes acquisition of process analytics innovator C Technolog
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance Reports record quarterly reven
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance WALTHAM, Mass. August 1, 2019 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for i
Read more →RGENRepligen to Report Second Quarter 2019 Financial Results
WALTHAM, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2019 financial results on Thursday, August 1, 2019. The Company will issue a press release before the market opens and will host a
Read more →RGENRepligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options
WALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of an aggregate of 1,587,000 shares of its common stock (the “Shares”) at a public o
Read more →RGENRepligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1,380,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gro
Read more →RGENRepligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes
WALTHAM, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced that it has commenced concurrent underwritten public offerings of $100,000,000 in shares of its common stock (the “Shares”) and $250,000,000 aggregate principal amou
Read more →RGENC TECHNOLOGIES, INC. FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2019 AND 2018 AND INDEPENDENT ACCOUNTANTS REVIEW REPORT C TECHNOLOGIES, INC. TABLE OF CONTENTS Page Independent Accountants Review Report 1 Financial
C TECHNOLOGIES, INC. FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2019 AND 2018 ACCOUNTANTS REVIEW REPORT C TECHNOLOGIES, INC. Page Independent Accountants Review Report 1 Financial Statements Balance Sheets 2 Statements of Income 3 Statements of Stockho
Read more →RGENRepligen to Present at Jefferies 2019 Healthcare Conference
WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Confer
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance Reports first quarter revenue o
Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance WALTHAM, MA May 9, 2019 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its firs
Read more →RGENRepligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growth Raises revenue guidance to $235-$241 million for full year 2019, representing 22%-25% organic growth Enters agreement to acquire analytics leader C Technologies Closes
Read more →RGENRepligen to Report First Quarter 2019 Financial Results
WALTHAM, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2019 financial results on Thursday, May 9, 2019. The Company will issue a press release before the market opens and will host a confe
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock Mass., April 29, 2019 Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, Repligen
Read more →RGENC TECHNOLOGIES, INC. FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2018 AND 2017 AND INDEPENDENT AUDITORS REPORT C TECHNOLOGIES, INC. TABLE OF CONTENTS Page Independent Auditors Report 1 Financial Statements Balance Shee
C TECHNOLOGIES, INC. FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2018 AND 2017 C TECHNOLOGIES, INC. Page Independent Auditors Report 1 Financial Statements Balance Sheets 2 Statements of Income 3 Statements of Stockholder s Equity 4 Statements of Cash Flo
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarte
Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results WALTHAM, MA, April 26, 2019 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technolo
Read more →RGENRepligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results
Proposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessing Adds a market leader in protein concentration measurement with proprietary and differentiated spectroscopy technology Complements and advances our sys
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2018 Financial Results Record quarterly revenue of $51.9 million represents 25% year-
Repligen Reports Fourth Quarter and Full Year 2018 Financial Results WALTHAM, MA February 21, 2019 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2018 Financial Results
Record quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-year growth Overall organic revenue growth was 25% for the fourth quarter and 17% for the year 2018 WALTHAM, Mass., Feb. 21, 2019
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2018 Financial Results
WALTHAM, Mass., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2018 financial results on Thursday, February 21, 2019. The Company will issue a press release before the market opens
Read more →RGENRepligen to Present at 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 37th Annual J.P. Morgan Healthcare conference being held January 7-10 at the W
Read more →RGENRepligen Reports Third Quarter 2018 Financial Results
Record quarterly revenue of $49.5 million represents 35% year-over-year growth Revenue guidance raised to $191-$194 million for full year 2018 WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2018 Financial Results Record quarterly revenue of $49.5 million represents 35% year-over-year growt
Repligen Reports Third Quarter 2018 Financial Results WALTHAM, MA November 1, 2018 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter and first nine months of 2018. P
Read more →RGENRepligen to Report Third Quarter 2018 Financial Results
- Webcast and Conference Call to Be Held Thursday, November 1, 2018 at 8:30 a.m. EDT - WALTHAM, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter of 2018 financial results on Thursday, Novem
Read more →RGENRepligen Reports Second Quarter 2018 Financial Results
Record quarterly revenue of $47.7 million represents 47% year-over-year growth Revenue guidance raised to $185-$190 million for full year 2018 WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2018 Financial Results Record quarterly revenue of $47.7 million represents 47% year-over-year grow
Repligen Reports Second Quarter 2018 Financial Results WALTHAM, MA August 2, 2018 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter and first half of 2018. Provided
Read more →RGENRepligen to Report Second Quarter 2018 Financial Results
WALTHAM, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter of 2018 financial results on Thursday, August 2, 2018. The Company will issue a press release before the market opens and will host
Read more →RGENRepligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand
WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligan
Read more →RGENRepligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity Ligands
WALTHAM, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced an agreement with Navigo Proteins GmbH (“Navigo”) for the advancement of exclusive novel affinity ligands
Read more →RGENRepligen to Present at the William Blair 2018 Growth Stock Conference
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Tony J. Hunt,
Read more →RGENRepligen to Present at Jefferies 2018 Global Healthcare Conference
WALTHAM, Mass., May 23, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of highly innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Jon K.
Read more →RGENRepligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will participate in the 15th Annual Craig-Hallum Ins
Read more →RGENRepligen Reports First Quarter 2018 Financial Results
Record quarterly revenue of $44.8M represents 46% year-over-year growth Revenue guidance raised to $182-$188 million for full year 2018 WALTHAM, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technolo
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2018 Financial Results Record quarterly revenue of $44.8M represents 46% year-over-year growth Reven
Repligen Reports First Quarter 2018 Financial Results WALTHAM, MA May 8, 2018 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2018. Provided in thi
Read more →RGENRepligen to Report First Quarter 2018 Financial Results
WALTHAM, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter of 2018 financial results on Tuesday, May 8, 2018. The Company will issue a press release before the market opens and will host a c
Read more →RGENRepligen Announces Market Launch of OPUS 80R, Reinforces Technology Leadership in Pre-Packed Chromatography
- First and only available 80 cm diameter pre-packed column to address large-scale clinical and commercial-scale manufacturing of biological drugs - WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioproce
Read more →RGENRepligen Reports Fourth Quarter 2017 Financial Results, Provides Guidance for 2018
- Revenue for 2017 increased by 35% to $141.2 million (36% at constant currency) - - GAAP EPS for 2017 more than doubled to $0.72, including a positive $0.24 impact of U.S. tax reform - - Spectrum outperforms on revenue guidance for first 5 months of ownership - WALTHAM, Mass.
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter 2017 Financial Results, Provides Guidance for 2018 - Revenue for 2017 increased by 35% to $141.2 mi
Repligen Reports Fourth Quarter 2017 Financial Results, Provides Guidance for 2018 - Revenue for 2017 increased by 35% to $141.2 million (36% at constant currency) - - GAAP EPS for 2017 more than doubled to $0.72, including a positive $0.24 impact of U.S. tax reform - - Spectr
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2017 Financial Results
WALTHAM, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018. The Company will issue a press release before the market opens and
Read more →RGENRepligen To Present at 36th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing-focused company delivering technology innovation to improve biologic drug manufacturing flexibility and efficiency, today announced that the Company will be presenting at
Read more →RGENRepligen Reports Third Quarter 2017 Financial Results
Record quarterly revenue of $36.6 million represents 48% year-over-year growth Year-to-date revenue of $99.6 million represents 26% year-over-year growth Spectrum contributes revenue of $7.6 million in first two months of ownership WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2017 Financial Results Record quarterly revenue of $36.6 million represents 48% year-over-year growt
Repligen Reports Third Quarter 2017 Financial Results WALTHAM, MA November 9, 2017 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter ended September 30, 2017. Detail
Read more →RGENRepligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands
Waltham, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended a long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen’s facilities in Waltham, MA and Lund, Sweden. Re
Read more →RGENRepligen to Report Third Quarter 2017 Financial Results
WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report third quarter of 2017 financial results on Thursday, November 9, 2017. The Company will issue a press release before the market opens and will host a
Read more →RGENRepligen Announces Analyst Day and Webcast
WALTHAM, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will host an institutional investor and analyst meeting on Friday, September 29, 2017 in New York City from 7:30 a.m.-10:00 a.m. (ET). The event theme, Bioproces
Read more →RGENRepligen to Present at Baird’s 2017 Global Healthcare Conference
WALTHAM, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will present at Baird’s 2017 Healthcare Conference in New York on Wednesday, September 6,
Read more →RGENRepligen Reports Second Quarter 2017 Financial Results
Record quarterly revenue of $32.5 million First half 2017 revenue growth of 16% or 18% at constant currency Enters agreement to acquire Spectrum, Inc., which closed August 1 Prices follow-on offering which netted proceeds of $129 million Raises EPS guidance for 2017 WALTHAM,
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2017 Financial Results Record quarterly revenue of $32.5 million First half 2017 revenue growth of
Repligen Reports Second Quarter 2017 Financial Results WALTHAM, MA August 3, 2017 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter ended June 30, 2017. Detailed in
Read more →RGENRepligen to Report Second Quarter 2017 Financial Results
WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report second quarter of 2017 financial results on Thursday, August 3, 2017. The Company will issue a press release before the market opens and will host a
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Repligen Corporation Prices Public Offering of Shares of Common Stock WALTHAM, MA
Repligen Corporation Prices Public Offering of Shares of Common Stock WALTHAM, MA June 27, 2017 Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,807,017 shares of its common stock at a public offering price of $42.75 per sh
Read more →RGENSpectrum, Inc. Table of Contents Page(s) Report of Independent Auditors 2 Combined Balance Sheets as of
Page(s) Report of Independent Auditors 2 Combined Balance Sheets as of April 1, 2017 (unaudited), December 31, 2016 and January 2, 2016 (restated) 3 Combined Statements of Comprehensive Income for the Quarters Ended April 1, 2017 and April 2, 2016 (unaudited), the Year E
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Corporation and Spectrum, Inc. to Join Forces Adds to Repligen a leader in bioprocess filtration with expertise in hollow
Repligen Corporation and Spectrum, Inc. to Join Forces June 23, 2017 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive merger agreement with privately-held Spectrum,
Read more →RGENRepligen Corporation and Spectrum, Inc. to Join Forces
- Adds to Repligen a leader in bioprocess filtration with expertise in hollow fiber technology - Strengthens flagship XCell™ ATF product line with an extensive filtration consumables portfolio - Diversifies markets beyond monoclonal antibody manufacturing into vaccine, recombin
Read more →RGENRepligen to Present at Jefferies’ 2017 Global Annual Healthcare Conference
WALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will present at Jefferies’ 2017 Global Annual Healthcare Conference, to be held June 6-9, 2
Read more →RGENRepligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will participate in the 14th Annual Craig-Hallum Institutional Investor Conference, to be h
Read more →RGENRepligen to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
WALTHAM, Mass., May 09, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas o
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2017 Financial Results Record quarterly revenue of $30.6 million reflects 22% year-over-year growth
Repligen Reports First Quarter 2017 Financial Results Record quarterly revenue of $30.6 million reflects 22% year-over-year growth or 24% at constant currency Company increases net income and EPS guidance WALTHAM, MA May 4, 2017 Repligen Corporation (NASDAQ:RGEN), a life scien
Read more →RGENRepligen Reports First Quarter 2017 Financial Results
Record quarterly revenue of $30.6 million reflects 22% year-over-year growth or 24% at constant currency Company increases net income and EPS guidance WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioproc
Read more →RGENRepligen to Report First Quarter 2017 Financial Results
WALTHAM, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter of 2017 financial results on Thursday, May 4, 2017. The Company will issue a press release before the market opens and will host a conf
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017 Fourth quarter 2016 revenue of $25.6 million ref
Repligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017 Fourth quarter 2016 revenue of $25.6 million reflects 19% growth Full year 2016 revenue of $104.5 reflects 25% growth Full year 2016 GAAP and adjusted operating income grew 16% and 20% respectiv
Read more →RGENRepligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017
Fourth quarter 2016 revenue of $25.6 million reflects 19% growth Full year 2016 revenue of $104.5 reflects 25% growth Full year 2016 GAAP and adjusted operating income grew 16% and 20% respectively WALTHAM, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:
Read more →RGENRepligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance for 2017
WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2016 financial results on Wednesday, February 22, 2017. The Company will issue a press release before the market opens an
Read more →RGENRepligen to Present at 35th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 35th Annual J.P. Morgan Healthcare conference being held January 9-12 at the W
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Acquires TangenX Technology Corporation Adds innovative single-use Sius TFF technology to downstream bioprocessing portfol
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Acquires TangenX Technology Corporation Adds innovative single-use Sius TFF technology to downstream bioprocessing portfolio WALTHAM, MA December 15, 2016 Repligen Corpo
Read more →RGENRepligen Acquires TangenX Technology Corporation
WALTHAM, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired TangenX Technology Corporation (“TangenX”) of Shrewsbury, MA, maker of the innovative
Read more →RGENRepligen to Participate in Stephens Inc. Fall Investment Conference 2016
WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in Stephens’ Fall Investment Conference,
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2016 Financial Results - Third quarter 2016 revenue of $24.7 million reflects 25% year-over-year gro
Repligen Reports Third Quarter 2016 Financial Results - Third quarter 2016 revenue of $24.7 million reflects 25% year-over-year growth WALTHAM, MA November 3, 2016 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today
Read more →RGENRepligen Reports Third Quarter 2016 Financial Results
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the third quarter ended September 30, 2016. Detailed in this press release are the Co
Read more →RGENRepligen to Report Third Quarter 2016 Financial Results
WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report third quarter 2016 financial results on Thursday, November 3, 2016. The Company will issue a press release before the market opens and will host a con
Read more →RGENRepligen Hires Ralf Kuriyel as Senior Vice President of Research & Development
WALTHAM, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the appointment of Ralf Kuriyel to the position of Senior Vice President of Research & Development (R&D).
Read more →RGENRepligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification
Complements Stainless Steel ATF Technology with Innovative Single-Use Format Improves Ease of Use for Biopharmaceutical Manufacturing Customers Offers Equivalent High Performance to Stainless Steel XCell™ ATF With Faster Implementation WALTHAM, Mass., Oct. 05, 2016 (GLOBE NEWS
Read more →RGENRepligen to Present at Baird Global Healthcare Conference 2016
WALTHAM, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive Officer, will present at Baird
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2016 Financial Results - Exceptional second quarter puts Company on track for 21%+ revenue growth f
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2016 Financial Results - Exceptional second quarter puts Company on track for 21%+ revenue growth for 2016- WALTHAM, MA August 4, 2016 Repligen
Read more →RGENRepligen Reports Second Quarter 2016 Financial Results
WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the second quarter ended June 30, 2016. Detailed in this press release are the Compan
Read more →RGENRepligen to Report Second Quarter 2016 Financial Results
WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report second quarter 2016 financial results on Thursday, August 4, 2016. The Company will issue a press release before the market opens and will host a conf
Read more →RGENRepligen to Present at Jefferies 2016 Healthcare Conference
WALTHAM, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive Officer, will present at the Je
Read more →RGENRepligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13th Annual Craig-Hallum Institutio
Read more →RGENRepligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021
WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (the “Company”) today announced the pricing of an underwritten public offering of $100 million aggregate principal amount of 2.125% Convertible Senior Notes due 2021 (the “Notes”). The Company has
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021 WALTHAM,
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021 WALTHAM, MA May 18, 2016 Repligen Corporation (NASDAQ: RGEN) (the Company ) has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due 2021
Read more →RGENRepligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (the “Company”) has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due 2021 (the “Notes”) in an underwritten offering which includes the grant to the
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2016 Financial Results - Record quarterly revenue of $25.1 million, reflecting 21% year-over-year gr
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2016 Financial Results - Record quarterly revenue of $25.1 million, reflecting 21% year-over-year growth - WALTHAM, MA May 5, 2016 Repli
Read more →RGENRepligen Reports First Quarter 2016 Financial Results
WALTHAM, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the first quarter ended March 31, 2016. Detailed in this press release are the Company
Read more →RGENRepligen to Report First Quarter 2016 Financial Results
WALTHAM, Mass., April 29, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter 2016 financial results on Thursday, May 5, 2016. The Company will issue a press release before the market opens and will host a confere
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Acquires Atoll GmbH - Broadens portfolio, expands customer base and increases capabilities in growing pre-packed chromatog
Repligen Acquires Atoll GmbH - Broadens portfolio, expands customer base and increases capabilities in growing pre-packed chromatography column market - WALTHAM, MA April 4, 2016 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology l
Read more →RGENRepligen Acquires Atoll GmbH
WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired Atoll GmBH (“Atoll”) of Weingarten, Germany, an innovator and manufacturer of MediaS
Read more →RGENRepligen Forms Scientific Advisory Board
WALTHAM, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced its formation of a Scientific Advisory Board (“SAB”) to provide thought leadership and oversight of the C
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Year 2015 Financial Results - Constant currency revenue growth of 45% for the fourth quarter, 4
Repligen Reports Fourth Quarter and Year 2015 Financial Results - Constant currency revenue growth of 45% for the fourth quarter, 47% for the year - - Gross margin expansion of 420 basis points to 57.8% for the year - - Non-GAAP adjusted EPS of $0.40, an increase of 67% for th
Read more →RGENRepligen Reports Fourth Quarter and Year 2015 Financial Results
- Constant currency revenue growth of 45% for the fourth quarter, 47% for the year - - Gross margin expansion of 420 basis points to 57.8% for the year - - Non-GAAP adjusted EPS of $0.40, an increase of 67% for the year - WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Repli
Read more →RGENRepligen Announces Extension of Long Term Supply Agreement for Protein A
WALTHAM, Mass., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that it has extended through 2019 a key long-term supply agreement with GE Healthcare for the manufacture of Protein A ligands at the Company’s facility in Lund, Sweden. In extend
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2015 Financial Results
WALTHAM, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016. The Company will issue a press release before the market opens and
Read more →RGENRepligen to Present at the Stifel 2015 Healthcare Conference
WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced its upcoming presentation at the Stifel 2015 Healthcare Conference, being held next week at the Lotte New York Palace. Tony J. Hunt, Repligen President and Chief Executive Officer
Read more →RGENRepligen Reports Third Quarter 2015 Financial Results
- Product Sales Increase 31% to $19.8 Million - - Conference Call and Webcast Today at 8:30 a.m. ET - WALTHAM, Mass., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported fin
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2015 Financial Results - Product Sales Increase 31% to $19.8 Million - - Conference Call and Webcast
Repligen Reports Third Quarter 2015 - Product Sales Increase 31% to $19.8 Million - - Conference Call and Webcast Today at 8:30 a.m. ET - WALTHAM, MA November 5, 2015 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, t
Read more →RGENRepligen to Report Third Quarter 2015 Financial Results
WALTHAM, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that it will report third quarter 2015 financial results on Thursday, November 5, 2015. The Company will issue a press release before the market opens and will host a conference c
Read more →RGENRepligen Appoints Glenn P. Muir to Board of Directors
WALTHAM, Mass., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that life sciences industry veteran Glenn P. Muir has been elected to its Board of Directors and appointed as a member of its Audit Committee. Mr. Muir brings over 30 years of ex
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Glenn P. Muir to Board of Directors WALTHAM, MA
Repligen Appoints Glenn P. Muir to Board of Directors WALTHAM, MA September 15, 2015 Repligen Corporation (NASDAQ:RGEN) today announced that life sciences industry veteran Glenn P. Muir has been elected to its Board of Directors and appointed as a member of its Audit Committee.
Read more →RGENRepligen Reports Second Quarter 2015 Financial Results
Product Sales Increase 38% to a Record $21.5 Million Conference Call and Webcast Today at 8:30 a.m. ET WALTHAM, Mass., Aug. 06, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported fi
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2015 Financial Results - Product Sales Increase 38% to a Record $21.5 Million - - Conference Call a
Repligen Reports Second Quarter 2015 Financial Results - Product Sales Increase 38% to a Record $21.5 Million - - Conference Call and Webcast Today at 8:30 a.m. ET - WALTHAM, MA August 6, 2015 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing
Read more →RGENRepligen to Report Second Quarter 2015 Financial Results
WALTHAM, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that it will report second quarter 2015 financial results on Thursday, August 6, 2015. The Company will issue a press release before the market opens and will host a conference ca
Read more →RGENRepligen to Present at Jefferies 2015 Healthcare Conference
WALTHAM, Mass., May 26, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced its upcoming presentation at the Jefferies 2015 Healthcare Conference to be held June 1-4, 2015 at the Grand Hyatt in New York. Tony J. Hunt, Repligen President and Chief Executive
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2015 Financial Results - Product Sales Increase 45% to a Record $20.8 Million - - Conference Call an
Repligen Reports First Quarter 2015 Financial Results - Product Sales Increase 45% to a Record $20.8 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, MA May 7, 2015 Repligen Corporation (NASDAQ:RGEN) today reported financial results for the first quart
Read more →RGENRepligen Reports First Quarter 2015 Financial Results
- Product Sales Increase 45% to a Record $20.8 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today reported financial results for the first quarter ended March 31, 2015. Below
Read more →RGENRepligen to Report First Quarter 2015 Financial Results
WALTHAM, Mass., April 29, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2015 financial results on Thursday, May 7, 2015. The Company will issue a press release before the market opens and will host a conference call
Read more →RGENRepligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Guidance
- Year 2014 Product Sales Increase 27% to a Record $60.4 Million - - Fourth Quarter Product Sales Increase 49% to $15.4 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Gu
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Guidance - Year 2014 Product Sales Incre
Read more →RGENRepligen to Report Year 2014 Financial Results and Provide 2015 Financial Guidance
WALTHAM, Mass., March 9, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and full year 2014 financial results on Friday, March 13, 2015. The Company will issue a press release prior to hosting a conference call on Mar
Read more →RGENRepligen Completes Expansion of U.S. Facility
WALTHAM, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) announced today that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Al
Read more →RGENRepligen to Present at 2015 Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference to be held February 11-12 at the Waldorf Astoria hotel in New York. Management is scheduled to partic
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Corporation Names Tony Hunt as Next Chief Executive Officer Wa
Repli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Corporation Names Tony Hunt as Next Chief Executive Officer Walter C. Herlihy to Retire Effective May
Read more →RGENRepligen Corporation Names Tony Hunt as Next Chief Executive Officer
WALTHAM, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) announced today that its Board of Directors has appointed Tony J. Hunt to be the Company's next Chief Executive Officer. Mr. Hunt, currently Repligen's Chief Operating Officer, will succeed Walte
Read more →RGENRepligen Receives Milestone Payment From Pfizer
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement")
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Receives Milestone Payment from Pfizer Company Reports Preliminary Reven
Repligen Receives Milestone Payment from Pfizer Company Reports Preliminary Revenue Results for 2014 and Provides Initial Revenue Guidance for 2015 WALTHAM, MA January 8, 2015 Repligen Corporation (NASDAQ:RGEN) announced today that on December 30, 2014, it received a $1 milli
Read more →RGENRepligen to Present at Stifel Healthcare Conference 2014
WALTHAM, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference 2014 on Wednesday, November 19 at 10:55 a.m. EST. The confer
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Third Quarter 2014 Financial Res
Repli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Third Quarter 2014 Financial Results - Product Revenue Increases 24%
Read more →RGENRepligen Reports Third Quarter 2014 Financial Results
Product Revenue Increases 24% to $15.2 Million Product Gross Profit Increases 26% to $8.2 Million Conference Call and Webcast Today at 8:30 a.m. EST WALTHAM, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today reported financial results for its thi
Read more →RGENRepligen to Present at Stephens Inc. Fall Investment Conference
WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on Wednesday, November 12 at 10:00 a.m. EST. The confe
Read more →RGENRepligen to Report Third Quarter 2014 Financial Results
WALTHAM, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report third quarter 2014 financial results on Thursday, November 6, 2014. The Company will issue a press release before the market opens and will host a conference c
Read more →RGENRepligen to Host Investor & Analyst Event on October 16
- Discussion of Biomanufacturing Trends and Technologies Will be Webcast - WALTHAM, Mass., Oct. 10, 2014 (GLOBE NEWSWIRE) --Repligen Corporation (Nasdaq:RGEN) today announced that the Company will host an Investor & Analyst Event on October 16, 2014 in New York. The event, which
Read more →RGENRepligen Reports Second Quarter 2014 Financial Results
Product Revenue Increases 19.5% to a Record $15.6 Million Product Gross Profit Increases 15.1% to a Record $8.9 Million Conference Call and Webcast Today at 8:30 a.m. EDT WALTHAM, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today reported financ
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Second Quarter 2014 Financial Results - Pr
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Second Quarter 2014 Financial Results - Product Revenue Increases 19.5% to a
Read more →RGENRepligen to Report Second Quarter 2014 Financial Results
WALTHAM, Mass., July 28, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report second quarter 2014 financial results on Monday, August 11, 2014. The Company will issue a press release before the market opens and will host a conference cal
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Hires Jon K. Snodgres as Chief Financial Officer WALTHAM, MA
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Hires Jon K. Snodgres as Chief Financial Officer WALTHAM, MA July 15, 2014 Repligen Corporation today announced
Read more →RGENRepligen Hires Jon K. Snodgres as Chief Financial Officer
WALTHAM, Mass., July 15, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Jon K. Snodgres has been named its Chief Financial Officer. Mr. Snodgres joins Repligen from his CFO role at Maquet Cardiovascular, a medical device company. Over the course
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Appoints Nicolas M. Barthelemy to Board of Directors WALTHAM, MA
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Appoints Nicolas M. Barthelemy to Board of Directors WALTHAM, MA June 12, 2014 Repligen Corporation today announced that it
Read more →RGENRepligen Appoints Nicolas M. Barthelemy to Board of Directors
WALTHAM, Mass., June 12, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation today announced that it has elected life sciences and biopharmaceutical industry veteran Nicolas M. Barthelemy to its Board of Directors. Mr. Barthelemy brings over 20 years of industry experience to the direc
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Acquires Bioprocessing Business of Refine Technology - Expands
Repligen Acquires Bioprocessing Business of Refine Technology - Expands Portfolio of Products to Improve Efficiencies in Biologic Drug Manufacturing - - Company Updates 2014 Financial Guidance - - Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, MA June 3, 2014 R
Read more →RGENRepligen Acquires Bioprocessing Business of Refine Technology
- Expands Portfolio of Products to Improve Efficiencies in Biologic Drug Manufacturing - - Company Updates 2014 Financial Guidance - - Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., June 3, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) annou
Read more →RGENRepligen to Present at Jefferies 2014 Global Healthcare Conference
WALTHAM, Mass., May 28, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Jefferies 2014 Global Healthcare Conference at 8:00 a.m. EDT on
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Reports First Quarter 2014 Financial Results - Pro
Repligen Reports First Quarter 2014 Financial Results - Product Revenue Increases 20% to a Record $14.3 Million - - Net Income Increases 83% to $4.3 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, MA May 8, 2014 Repligen Corporation (NASDAQ:RGEN) tod
Read more →RGENRepligen Reports First Quarter 2014 Financial Results
- Product Revenue Increases 20% to a Record $14.3 Million - - Net Income Increases 83% to $4.3 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., May 8, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today reported financial results f
Read more →RGENRepligen Hires Former Life Technologies Executive Tony J. Hunt as Chief Operating Officer
WALTHAM, Mass., May 6, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation, a life sciences company focused on the manufacture and commercialization of bioprocessing products, today announced the appointment of Tony J. Hunt to the newly created position of Chief Operating Officer. Mr.
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Hires Former Life Technologies Executive Tony J. Hunt as Chief
Repli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Hires Former Life Technologies Executive Tony J. Hunt as Chief Operating Officer May 6, 2014 Repligen Corporation, a
Read more →RGENRepligen to Report First Quarter 2014 Financial Results
WALTHAM, Mass., April 25, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2014 financial results on Thursday, May 8, 2014. The Company will issue a press release before the market opens and will host a conference call
Read more →RGENRepligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market
WALTHAM, Mass., March 26, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, today announced the commercial launch of its OPUS 45 cm diameter columns ("OPUS 45") with the la
Read more →RGENRepligen Reports Full Year and Fourth Quarter 2013 Financial Results
- 2013 Product Revenue Growth of 13.5% - - Year-over-Year Net Income Up 13.7% to $16.1 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EST - WALTHAM, Mass., March 6, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today reported financial result
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Reports Full Year and Fourth Quarter 2013 Financial Results - 2013 Produ
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Reports Full Year and Fourth Quarter 2013 Financial Results - 2013 Product Revenue Growth of 13.5% - - Year-over-Year Net
Read more →RGENRepligen to Report Fourth Quarter and Fiscal Year 2013 Financial Results
WALTHAM, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and fiscal year 2013 financial results on Thursday, March 6, 2014. The Company will issue a press release before the market opens and will host
Read more →RGENRepligen Announces Asset Purchase Agreement With BioMarin for HDACi Portfolio
WALTHAM, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) announced today that it has entered into an asset purchase agreement with BioMarin Pharmaceutical Inc. ("BioMarin") to advance Repligen's histone deacetylase inhibitor (HDACi) portfolio. The HDAC
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Announces Asset Purchase Agreement with BioMarin for HDACi Portfolio Inc
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Announces Asset Purchase Agreement with BioMarin Includes Preclinical Compounds for Potential Treatment of Friedreich s Ata
Read more →RGENRepligen to Present at the 25th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the 25th Annual Piper Jaffray Healthcare Conference on Tuesday, De
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors WALTHAM
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors WALTHAM, MA November 19, 2013 Repligen Corporation to
Read more →RGENRepligen Appoints Biogen Idec Executive John G. Cox to Board of Directors
WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation today announced that it has elected to its Board of Directors John G. Cox, Executive Vice President of Pharmaceutical Operations & Technology for Biogen Idec Inc., a leading biopharmaceutical company. Mr. Cox
Read more →RGENRepligen Reports Third Quarter 2013 Financial Results
- Product Revenue Grows 10% for the Quarter - - Net Income Grows 226% to $5.9 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EST - WALTHAM, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today reported financial results for the
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Reports Third Quarter 2013 Financial Results - Product Revenue
Repli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Reports Third Quarter 2013 Financial Results - Product Revenue Grows 10% for the Quarter - - Net Income Grows 226
Read more →RGENRepligen to Present at the 2013 Stephens Fall Investment Conference
WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stephens Fall Investment Conference on Wednesday, November 13 a
Read more →RGENRepligen Completes Expansion of U.S. Manufacturing Facility
WALTHAM, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure tha
Read more →RGENRepligen to Report Third Quarter 2013 Financial Results
WALTHAM, Mass., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report third quarter 2013 financial results on Thursday, November 7, 2013. The Company will issue a press release before the market opens, and will host a conference
Read more →RGENRepligen to Present at the Stifel Healthcare Conference 2013
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference on Wednesday, September 11, 2013
Read more →RGENRepligen Receives First Milestone Payment From Pfizer Under Licensing Agreement for Spinal Muscular Atrophy Program
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) announced today that it has received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the developme
Read more →RGENRepligen Reports Second Quarter 2013 Financial Results
- Product Revenue Grows 12% for the Quarter on Record Bioprocessing Sales - - Net Income Grows 189% to $4.5 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today repor
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Second Quarter 2013 Financial Results - Pr
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Second Quarter 2013 Financial Results - Product Revenue Grows 12% for the Quarter on Record Biopr
Read more →RGENRepligen to Report Second Quarter 2013 Financial Results
WALTHAM, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report second quarter 2013 financial results on Thursday, August 1, 2013. The Company will issue a press release before the market opens, and will host a conference c
Read more →RGENRepligen CEO to Present at Jefferies 2013 Global Healthcare Conference
WALTHAM, Mass., May 23, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 FOR IMMEDIATE RELEASE Repligen Reports First Quarter 2013 Financial Results - Tot
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 FOR IMMEDIATE RELEASE Repligen Reports First Quarter 2013 Financial Results - Total Revenue and Bioprocessing Revenue Grow 28% Over
Read more →RGENRepligen Reports First Quarter 2013 Financial Results
- Total Revenue and Bioprocessing Revenue Grow 28% Over First Quarter 2012 - - Net Income Increases 91% to $2.3 million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today re
Read more →RGENRepligen to Report First Quarter 2013 Financial Results
WALTHAM, Mass., April 23, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that it will report financial results for the first quarter 2013 on Thursday, May 2, 2013. The Company will issue a press release prior to market opening and will host a webcast
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Fourth Quarter and Full Year 201
Repli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Financial Guida
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Financial Guidance for 2013
- Bioprocessing Revenue Increases to $42 Million, Total Revenue Reaches $63 Million in 2012 - - Year-over-Year Net Income Increases by $18 Million - WALTHAM, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today reported financial results for its fou
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2012 Financial Results
WALTHAM, Mass., March 1, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) announced today that it will report financial results for the fourth quarter and year ended December 31, 2012 on March 7. On this date, the Company will issue a press release prior to the opening
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Pr
Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program WALTHAM, MA January 03, 2013 Repligen Corporation (NASDAQ:RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen s spi
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Third Quarter 2012 Financial Results - Net
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 FOR IMMEDIATE RELEASE Telefax: (781) 250-0115 Repligen Reports Third Quarter 2012 Financial Results - Net Income Triples on 94% Increase in Bioprocessin
Read more →RGENRepligen Initiates Phase 1b Trial of RG3039 for Spinal Muscular Atrophy Licensed From Families of SMA
ELK GROVE VILLAGE, Ill., Sept. 26, 2012 (GLOBE NEWSWIRE) -- Repligen Corporation has initiated a Phase 1b clinical study of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA). The primary objectives of the study are to furth
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Appoints Jonathan I. Lieber as CFO - Former CFO of Xcellerex, Inc. Joins
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Appoints Jonathan I. Lieber as CFO - Former CFO of Xcellerex, Inc. Joins Repligen Executive Management Team - September 21
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 Repligen Announces Strategic Focus on Bioprocessing Business an
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 Repligen Announces Strategic Focus on Bioprocessing Business and Reports Second Quarter 2012 Financia
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: (781) 250-0111 Telefax: (781) 250-0115 Repligen Receives Complete Response Letter from FDA for RG1068
Repligen Receives Complete Response Letter from FDA for RG1068 NDA WALTHAM, MA June 22, 2012 Repligen Corporation (NASDAQ:RGEN) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company s New Drug
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Walter C. Herlihy President and CEO 781.419.1900 Repligen Announces Support
Repligen Announces Support of Amended Stockholder Proposal WALTHAM, MA May 7, 2012 Repligen Corporation (NASDAQ:RGEN) today announced that it will support an amended stockholder proposal based upon an agreement with Ronald L. Chez, the proponent of the proposal. Mr. Chez submit
Read more →RGENRepli Gen FOR IMMEDIATE RELEASE Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Walter C. Herlihy President and CEO 781.419.
Repligen Reports First Quarter 2012 Financial Results; Conference Call at 8:30 a.m. Today - Strong Bioprocessing Revenue Growth Following December 2011 Acquisition - WALTHAM, MA May 3, 2012 Repligen Corporation (NASDAQ:RGEN) today reported results for its first quarter ended M
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 CONTACT: Walter C. Herlihy President & CEO 781-419-1900 Replige
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee M
Read more →RGENRepligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA)
ELK GROVE VILLAGE, Ill., April 25, 2012 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatmen
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 CONTACT: Laura L. Whitehouse VP, Market Development (781) 419-1
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 VP, Market Development Repligen Reports Financial Results for the Quarter and Nine-Month Fiscal Year E
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 CONTACT: Laura L. Whitehouse Vice President, Market Development
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 Vice President, Market Development Repligen Announces Submission of Marketing Authorization Application in EU fo
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE CONTACT: Walter C. Herlihy, PhD President and Chief Executive O
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE Repligen Announces Submission of New Drug Application for SecreFlo for Improved Pancreatic Imaging In Patients wi
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 CONTACT: Walter C. Herlihy, PhD President and Chief E
Repli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 Repligen Acquires Business of Novozymes Biopharma Sweden AB Creates World-Leading Supplier of Product
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE CONTACT: Laura L. Whitehouse Vice President, Market Development
Vice President, Market Repligen Reports Second Quarter Fiscal Year 2012 Financial Results Achieves Record Bioprocessing Product Sales WALTHAM, MA October 27, 2011 Repligen Corporation (NASDAQ: RGEN) today reported results for the second quarter of fiscal year 2012, ended Septe
Read more →RGENRepligen Reports First Quarter Fiscal Year 2012 Financial Results
Repligen Reports First Quarter Fiscal Year 2012 Financial Results, July 27, 2011 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 FOR IMMEDIATE RELEASE Telephone: 781-250-01111 Telefax: 781-250-0115 Repligen Reports First Quarter Fi
Read more →RGENRepli Gen FOR IMMEDIATE RELEASE Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Walter Herlihy President & Chief Executive O
Repli Gen FOR IMMEDIATE RELEASE Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Walter Herlihy President & Chief Executive Officer (781) 419-1900 Laura Whitehouse Vice President,
Read more →RGENRepli Gen FOR IMMEDIATE RELEASE Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Walter C. Herlihy, PhD President and Chief E
Repli Gen FOR IMMEDIATE RELEASE Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Walter C. Herlihy, PhD President and Chief Executive Officer (781) 419-1900 Laura L. Whitehouse VP, Ma
Read more →RGENRepligen Reports Third Quarter Fiscal Year 2011 Financial Results
Repligen Reports Third Quarter Fiscal Year 2011 Financial Results, February 9, 2011 Vice President, Market Repligen Reports Third Quarter Fiscal Year 2011 Financial Results WALTHAM, MA February 9, 2011 Repligen Corporation (NASDAQ: RGEN) today reported results for the third q
Read more →RGENRepligen Reports Second Quarter Fiscal Year 2011 Financial Results
Repligen Reports Second Quarter Fiscal Year 2011 Financial Results, November 2, 2010 Vice President, Market Repligen Reports Second Quarter Fiscal Year 2011 Financial Results WALTHAM, MA November 2, 2010 Repligen Corporation (NASDAQ: RGEN) today reported results for the second
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE CONTACT: Laura Whitehouse Vice President, Market Deve
Repli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE Vice President, Market Repligen Reports Fourth Quarter and Fiscal Year 2010 Financial Results WALTHAM, MA Ju
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 CONTACT: Walter C. Herlihy, PhD President and Chief Executive O
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 Repligen Reports Preliminary Fiscal Year 2010 Financial Results and Provides Financial Guidance and De
Read more →RGENRepli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE CONTACT: Laura Whitehouse VP, Market Development (781
Repli Gen Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE VP, Market Development Repligen Reports Third Quarter Fiscal Year 2010 Financial Results WALTHAM, MA Febr
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Laura Whitehouse VP, Market Development (781) 419-1812
FOR IMMEDIATE RELEASE Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 VP, Market Development Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein
Read more →RGENRepligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE CONTACT: Laura Whitehouse VP, Market Development (781) 419-1812
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 FOR IMMEDIATE RELEASE VP, Market Development Repligen Reports Second Quarter Fiscal Year 2010 Financial Results WALTHAM, MA Novem
Read more →RGENRepli Gen FOR IMMEDIATE RELEASE Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Laura Whitehouse VP, Market Development (781
VP, Market Development Repligen Reports First Quarter Fiscal Year 2010 Financial Results WALTHAM, MA August 6, 2009 Repligen Corporation (NASDAQ: RGEN) today reported results for the first quarter fiscal year 2010, ended June 30, 2009. Total revenue for the quarter was $5,061,
Read more →RGENRepligen Corporation 41 Seyon Street Repli Gen Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 CONTACT: Laura Whitehouse VP Market Development (781)
Repligen Corporation 41 Seyon Street Repli Gen Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 FOR IMMEDIATE RELEASE Telefax: 781-250-0115 VP Market Development Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results WALTHAM
Read more →RGENRepliGen FOR IMMEDIATE RELEASE Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Telephone: 781-250-0111 Telefax: 781-250-0115 CONTACT: Walter C. Herlihy, Ph.D. President and Chief
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results WALTHAM, MA February 5, 2009 Repligen Corporation (NASDAQ: RGEN) today reported results for the third quarter of fiscal year 2009, ended December 31, 2008. Total revenue for the quarter was $6,018,000 compared to
Read more →Competitive Position
How RGEN ranks across every disease it competes inCompetitive Position is a premium feature
See how RGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial